scholarly journals Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations

1996 ◽  
Vol 63 (5) ◽  
pp. 722-728 ◽  
Author(s):  
B M Winklhofer-Roob ◽  
M A van’t Hof ◽  
D H Shmerling
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin E ◽  
Alpha Tocopherol ◽  
Tocopheryl Acetate ◽  
Oral Vitamin ◽  
Vitamin E Supplementation

scholarly journals ROLE OF VITAMIN C AND VITAMIN E ON HYPERTENSION

2019 ◽  
pp. 95-98 ◽  
Author(s):  
SANTHOSHAKUMARI TMJ ◽  
MATHIVANAN J ◽  
JEYALAKSHMI J
Keyword(s):  
Vitamin E ◽  
Vitamin C ◽  
Oral Vitamin ◽  
Test Analysis ◽  
Oral Supplementation ◽  
Clinical Events ◽  
Significant Difference ◽  
Group 2 ◽  
Vitamin E Supplementation

Objective: Both Vitamin C and Vitamin E supplementation were associated with reduction in blood pressure (BP) in observational studies, although, results of clinical trials are inconsistent. The objective of our study is to conduct a clinical trial to observe the effects of oral supplementation of Vitamin C and Vitamin E on BP. Methods: About 60 non-teaching staffs of our college with systolic BP more than 130 mmHg and diastolic BP more than 90 mmHg were taken as subjects and divided into two groups. Initial BP and BP after oral Vitamin C, 500 mg/day for a period of 12weeks to Group 1 and initial BP and BP after oral Vitamin E, 200 IU/day, for a period of 12 weeks to Group 2 were recorded. Results: Statistical analysis was done by paired t-test, analysis of variance (ANOVA), and least significant difference (LSD) tests. *p<0.05 was considered statistically significant. Systolic 2 and diastolic 2 – after 3 months of supplementation showed 0.161 and 0.161 which is not significant. ANOVA and LSD tests show no significant results. Conclusion: Long-term trials on the effects of Vitamin C and Vitamin E supplementation on BP and clinical events are needed.

scholarly journals A new water-soluble oral vitamin E formulation in cystic fibrosis (CF) children

2010 ◽  
Vol 9 ◽  
pp. S91 ◽  
Author(s):  
A. Munck ◽  
J.L. Giniès ◽  
F. Huet ◽  
N. Wizla ◽  
M. Gérardin ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin E ◽  
Water Soluble ◽  
Oral Vitamin

Retrolental Fibroplasia and Vitamin E in the Preterm Infant—Comparison of Oral Versus Intramuscular:Oral Administration

PEDIATRICS ◽  
1984 ◽  
Vol 73 (2) ◽  
pp. 238-249
Author(s):  
Helen M. Hittner ◽  
Michael E. Speer ◽  
Arnold J. Rudolph ◽  
Cindy Blifeld ◽  
Prabhujeet Chadda ◽  
...  
Keyword(s):  
Vitamin E ◽  
Very Low Birth Weight ◽  
Plasma Vitamin ◽  
Oral Vitamin ◽  
Low Birth Weight Infants ◽  
Retrolental Fibroplasia ◽  
Intramuscular Injections ◽  
Significant Difference ◽  
Plasma Vitamin E ◽  
Vitamin E Supplementation

To evaluate the efficacy of four early intramuscular injections of vitamin E given in addition to continuous minimal oral vitamin E supplementation, 168 very low-birth-weight infants (≤1,500 g) have enrolled in a randomized, double-masked, clinical study. All infants received vitamin E orally, 100 mg/kg/d. In addition, on days 1, 2, 4, and 6, seventy-nine infants received vitamin E intramuscularly, 15, 10, 10, and 10 mg/kg, respectively. On the same days, 89 control infants received placebo intramuscular injections. Multivariate analysis of the 135 infants who survived ≥10 weeks showed no significant difference in the development of severe retrolental fibroplasia between these two supplementation schedules (P = .86). Plasma vitamin E levels never exceeded a mean of 3.3 mg/100 mL, and no toxicity was observed. Ultrastructural analyses of seven pairs of whole eye donations from infants receiving IM vitamin E demonstrated identical kinetics of gap junction formation between adjacent spindle cells as compared with 13 pairs of whole eye donations from control infants (P &gt; .3). Therefore, oral vitamin E supplementation affords retinal protection against the development of severe retrolental fibroplasia when initiated on the first day of life and maintained continuously until retinal vascularization is complete.

Relative Bioavailabilities of Natural and Synthetic Vitamin E Formulations Containing Mixed Tocopherols in Human Subjects

1999 ◽  
Vol 69 (2) ◽  
pp. 92-95 ◽  
Author(s):  
Chopra ◽  
Bhagavan
Keyword(s):  
Vitamin E ◽  
Animal Models ◽  
Human Subjects ◽  
Alpha Tocopherol ◽  
Tocopheryl Acetate ◽  
Normal Male ◽  
Gamma Tocopherol ◽  
Synthetic Vitamin ◽  
Male Subjects ◽  
Natural And Synthetic

There are several reports in the literature on the relative bioavailabilities of RRR (natural) vs. all-rac (synthetic) forms of vitamin E in humans and animal models but none on the bioavailability of alpha-tocopherol in mixed vitamin E formulations. In the present study we examined the bioavailability of alpha-tocopherol in a typical commercially available product containing mixed tocopherols. We also tested a formulation containing all-rac-alpha-tocopherol with mixed tocopherols for purposes of comparison along with straight RRR-and all-rac-alpha-tocopheryl acetate as reference products. Normal male subjects were given one of the four formulations of vitamin E (800 IU per day in softgel capsule form for 10 days): 1. All-rac-alpha-tocopheryl acetate, 2. RRR-alpha-tocopheryl acetate, 3. RRR-alpha-tocopherol with mixed tocopherols, and 4. all-rac-alpha-tocopherol with mixed tocopherols. Both serum alpha- and gamma-tocopherols were determined by HPLC at baseline, and at days 2, 4, 7 and 10. The values for alpha- at baseline and 10 days were 0.80, 0.80, 0.80 & 0.79 mg/dl and 1.67, 1.72, 1.76 & 1.62 mg/dl. The values for gamma- were 0.28, 0.29, 0.30 & 0.29 mg/dl and 0.11, 0.08, 0.10 & 0.10 mg/dl. Thus the data show that a) the bioavailability of RRR-and all-rac-alpha-tocopherols is not affected by other tocopherols, and b) both RRR-and all-rac-alpha-tocopherol (free or esterified) significantly suppress the serum gamma tocopherol to the same extent. Furthermore, since there was no difference in the serum values of alpha-tocopherol between RRR-and all-rac-vitamin E given the same dose as IUs, the data also support the currently accepted ratio of 1.36 for the biopotency of RRR- vs. all-rac-alpha-tocopheryl acetate.

Vitamin E supplementation in people with cystic fibrosis

2014 ◽  
Author(s):  
Peter O Okebukola ◽  
Sonal Kansra ◽  
Joanne Barrett
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin E ◽  
Vitamin E Supplementation

Vitamin E Supplementation Increases LDL Resistance to ex vivo Oxidation in Hemodialysis Patients

2003 ◽  
Vol 73 (4) ◽  
pp. 290-296 ◽  
Author(s):  
Badiou ◽  
Cristol ◽  
Morena ◽  
Bosc ◽  
Carbonneau ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin E ◽  
High Performance ◽  
Ex Vivo ◽  
Density Lipoprotein ◽  
Thiobarbituric Acid ◽  
Hemodialysis Patients ◽  
Ldl Oxidation ◽  
Oral Vitamin ◽  
Vitamin E Supplementation

Background: Oxidative stress and alterations in lipid metabolism observed in hemodialysis patients potentiate the low-density lipoprotein (LDL) oxidability, recognized as a key event during early atherogenesis. Objective: To explore the effects of an oral vitamin E supplementation on oxidative stress markers and LDL oxidability in hemodialysis patients. Methods: Fourteen hemodialysis patients and six healthy volunteers were given oral vitamin E (500 mg/day) for six months. Oxidative stress was assessed using: plasma and lipoprotein vitamin E levels [high-performance liquid chromatography (HPLC) procedure]; thiobarbituric acid reactive substances (TBARS, Yaggi method); and copper-induced LDL oxidation. All parameters were evaluated before initiation of vitamin E supplementation, and at three and six months thereafter. Results: At baseline, a significantly higher TBARS concentration and a higher LDL oxidability were observed in hemodialysis patients when compared to controls. After six months of vitamin E supplementation, TBARS and LDL oxidability were normalized in hemodialysis patients. Conclusion: Our data confirm that hemodialysis patients are exposed to oxidative stress and increased susceptibility to ex vivo LDL oxidation. Since oral vitamin E supplementation prevents oxidative stress and significantly increases LDL resistance to ex vivo oxidation, supplementation by natural antioxidants such as vitamin E may be beneficial in hemodialysis patients.

Vitamin E decreases hepatic levels of aldehyde-derived peroxidation products in rats with iron overload

1996 ◽  
Vol 270 (2) ◽  
pp. G376-G384 ◽  
Author(s):  
S. Parkkila ◽  
O. Niemela ◽  
R. S. Britton ◽  
K. E. Brown ◽  
S. Yla-Herttuala ◽  
...  
Keyword(s):  
Lipid Peroxidation ◽  
Vitamin E ◽  
Iron Overload ◽  
Kupffer Cells ◽  
Laser Scanning ◽  
Laser Scanning Microscopy ◽  
Alpha Tocopherol ◽  
Confocal Laser ◽  
Hepatocellular Injury ◽  
Vitamin E Supplementation

Hepatic iron overload can cause lipid peroxidation with the formation of aldehydic products, hepatocellular injury, and fibrosis. Vitamin E (alpha-tocopherol) may prevent peroxidation-induced hepatic damage. We used confocal laser scanning microscopy, digital image analysis, and immunohistochemical methods to quantitate aldehyde-derived peroxidation products in the liver of rats with experimental iron overload with or without supplemental vitamin E. A strong autofluorescent reaction colocalizing with iron deposits was present in the livers of iron-loaded rats. Fluorescent granules were unevenly distributed in the cytosol of both hepatocytes and Kupffer cells in the periportal regions. Immunohistochemical studies revealed the presence of malon-dialdehyde adducts in the periportal regions of the ironloaded rats. Vitamin E supplementation markedly reduced the fluorescence intensity and the amount of aldehyde-derived peroxidation products and changed the distribution of stainable iron and iron-associated peroxidation products such that their levels were much decreased in Kupffer cells. These results indicate that aldehyde-derived covalent chemical addition products are formed in the liver in iron overload. Vitamin E supplementation markedly reduces the amount of these compounds and changes their cellular distribution. These findings should be implicated in the role of antioxidant therapy in conditions causing iron overload and lipid peroxidation.

scholarly journals Serum Metabolomic Response to Low and High Dose Vitamin E Supplementation in Two Randomized Controlled Trials

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1810-1810
Author(s):  
Jiaqi Huang ◽  
Stephanie Weinstein ◽  
Wendy Mack ◽  
Howard Hodis ◽  
Demetrius Albanes
Keyword(s):  
Prostate Cancer ◽  
Vitamin E ◽  
Cancer Prevention ◽  
Low Dose ◽  
Alpha Tocopherol ◽  
P Value ◽  
High Dose ◽  
Atbc Study ◽  
High Dose Vitamin ◽  
Vitamin E Supplementation

Abstract Objectives Vitamin E is an essential micronutrient and critical human antioxidant that has been tested for cancer and cardiovascular preventative effects for decades with conflicting results. For example, prostate cancer incidence was reduced by a low-dose vitamin E supplement in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, but the findings were not replicated by high-dose vitamin E trials such as the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The present investigation examined the serum metabolomic responses to low- and high-dose vitamin E supplementation in order to gain biological insight into the divergent trial outcomes. Methods We examined baseline and on-study serum samples for 154 men randomly assigned to receive 400 IU vitamin E (as alpha-tocopheryl acetate; ATA) or placebo daily in the Vitamin E Atherosclerosis Prevention Study (VEAPS), and 100 men administered 50 IU ATA or placebo daily in the ATBC Study. Over 970 known metabolites were identified using an ultrahigh-performance LC-MS/MS platform. Linear regression models estimated the change in serum metabolites of men supplemented with vitamin E to those assigned to placebo in VEAPS compared with ATBC. Results Serum alpha-carboxyethyl hydrochroman (CEHC) sulfate, alpha-tocopherol, and beta-/gamma-tocopherol were significantly altered by supplementation with ATA in both the VEAPS and ATBC trials (all P-values ≤ 5.1 × 10−5, the Bonferroni multiple-comparisons corrected statistical threshold). Serum C22 lactone sulfate was also significantly decreased in response to the high-dose vitamin E supplement in VEAPS (β = −0.70, P-value = 8.1 × 10−6), but not altered in the low-dose ATBC trial (β = −0.17, P-value = 0.4). Additionally, changes in several androgenic steroid metabolites were strongly related to the vitamin E supplement-associated change in C22 lactone sulfate only in the high-dose VEAPS trial. Conclusions We found evidence of a dose-dependent vitamin E supplementation effect on a novel C22 lactone sulfate compound as well as several androgenic steroids that may have relevance to previous controlled trial findings for prostate cancer. Funding Sources This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, U.S. Public Health Service, Department of Health and Human Services.

Sign in / Sign up

Export Citation Format

Share Document